Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion type Assertion NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_head.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion description "[Vasoactive intestinal peptide (VIP) has been considered as a promising drug candidate for asthma and COPD because of its potent immunomodulating and anti-inflammatory activities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_provenance.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion evidence source_evidence_predicted NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_provenance.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion SIO_000772 21419198 NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_provenance.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion wasDerivedFrom rgd-20150221 NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_provenance.
- NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_assertion wasGeneratedBy ECO_0000218 NP43377.RAUBOzBEUn3B3h1yyYKp4H0OSXicjG9_gbE04n-UkIPm0130_provenance.